| Reference |
|---|
Suina K, Tsuchihashi K, Yamasaki J, Kamenori S, Shintani S, Hirata Y, et al. Epidermal growth factor receptor promotes glioma progression by regulating xCT and GluN2B-containing N-methyl-d-aspartate-sensitive glutamate receptor signaling. Cancer Sci. 2018;109:3874-3882 pubmed publisher |
Stanley A, Ashrafi G, Seddon A, Modjtahedi H. Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell lines. Sci Rep. 2017;7:3964 pubmed publisher |
Ishibashi M, Neri S, Hashimoto H, Miyashita T, Yoshida T, Nakamura Y, et al. CD200-positive cancer associated fibroblasts augment the sensitivity of Epidermal Growth Factor Receptor mutation-positive lung adenocarcinomas to EGFR Tyrosine kinase inhibitors. Sci Rep. 2017;7:46662 pubmed publisher |
Merrouche Y, Fabre J, Curé H, Garbar C, Fuselier C, Bastid J, et al. IL-17E synergizes with EGF and confers in vitro resistance to EGFR-targeted therapies in TNBC cells. Oncotarget. 2016;7:53350-53361 pubmed publisher |
Zhu X, Jiang H, Li J, Xu J, Fei Z. Anticancer Effects of Paris Saponins by Apoptosis and PI3K/AKT Pathway in Gefitinib-Resistant Non-Small Cell Lung Cancer. Med Sci Monit. 2016;22:1435-41 pubmed |
Staberg M, Michaelsen S, Olsen L, Nedergaard M, Villingshøj M, Stockhausen M, et al. Combined EGFR- and notch inhibition display additive inhibitory effect on glioblastoma cell viability and glioblastoma-induced endothelial cell sprouting in vitro. Cancer Cell Int. 2016;16:34 pubmed publisher |
Kurimoto R, Iwasawa S, Ebata T, Ishiwata T, Sekine I, Tada Y, et al. Drug resistance originating from a TGF-β/FGF-2-driven epithelial-to-mesenchymal transition and its reversion in human lung adenocarcinoma cell lines harboring an EGFR mutation. Int J Oncol. 2016;48:1825-36 pubmed publisher |
Oda M, Iwaya K, Kikuchi R, Kobayashi T, Yoneda T, Nishikawa K, et al. Stathmin is involved in the cooperative effect of Zoledronic acid and gefitinib on bone homing breast cancer cells in vitro. J Bone Oncol. 2012;1:40-6 pubmed publisher |
Li L, Huang W, Li K, Zhang K, Lin C, Han R, et al. Metformin attenuates gefitinib-induced exacerbation of pulmonary fibrosis by inhibition of TGF-β signaling pathway. Oncotarget. 2015;6:43605-19 pubmed publisher |
Khelwatty S, Essapen S, Seddon A, Fan Z, Modjtahedi H. Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers. Br J Cancer. 2015;113:1010-9 pubmed publisher |
Lindholm P, Sivapurapu N, Jovanovic B, Kajdacsy Balla A. Monocyte-Induced Prostate Cancer Cell Invasion is Mediated by Chemokine ligand 2 and Nuclear Factor-κB Activity. J Clin Cell Immunol. 2015;6: pubmed |
Curran S, Vantangoli M, Boekelheide K, Morgan J. Architecture of Chimeric Spheroids Controls Drug Transport. Cancer Microenviron. 2015;8:101-9 pubmed publisher |
Kleczko E, Kim J, Keysar S, Heasley L, Eagles J, Simon M, et al. An Inducible TGF-?2-TGF?R Pathway Modulates the Sensitivity of HNSCC Cells to Tyrosine Kinase Inhibitors Targeting Dominant Receptor Tyrosine Kinases. PLoS ONE. 2015;10:e0123600 pubmed publisher |
Bill A, Gutierrez A, Kulkarni S, Kemp C, Bonenfant D, Voshol H, et al. ANO1/TMEM16A interacts with EGFR and correlates with sensitivity to EGFR-targeting therapy in head and neck cancer. Oncotarget. 2015;6:9173-88 pubmed |
Moody T, Nuche Berenguer B, Moreno P, Jensen R. CI-988 Inhibits EGFR Transactivation and Proliferation Caused by Addition of CCK/Gastrin to Lung Cancer Cells. J Mol Neurosci. 2015;56:663-72 pubmed publisher |
Zhou Y, Zhang Y, Zou H, Cai N, Chen X, Xu L, et al. The multi-targeted tyrosine kinase inhibitor vandetanib plays a bifunctional role in non-small cell lung cancer cells. Sci Rep. 2015;5:8629 pubmed publisher |
Wang X, Song H, Yu Q, Liu Q, Wang L, Liu Z, et al. Ad-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibitor gefitinib. Oncol Rep. 2015;33:526-32 pubmed publisher |
Qawasmi I, Shmuel M, Eyal S. Interactions of ABCG2 (BCRP) with epidermal growth factor receptor kinase inhibitors developed for molecular imaging. Front Pharmacol. 2014;5:257 pubmed publisher |
Sakurai M, Ozaki Y, Okuzaki D, Naito Y, Sasakura T, Okamoto A, et al. Gefitinib and luteolin cause growth arrest of human prostate cancer PC-3 cells via inhibition of cyclin G-associated kinase and induction of miR-630. PLoS ONE. 2014;9:e100124 pubmed publisher |
Li L, Han R, Xiao H, Lin C, Wang Y, Liu H, et al. Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal. Clin Cancer Res. 2014;20:2714-26 pubmed publisher |
Moody T, Chan D, Mantey S, Moreno P, Jensen R. SR48692 inhibits non-small cell lung cancer proliferation in an EGF receptor-dependent manner. Life Sci. 2014;100:25-34 pubmed publisher |
Joannes A, Grelet S, Duca L, Gilles C, Kileztky C, Dalstein V, et al. Fhit regulates EMT targets through an EGFR/Src/ERK/Slug signaling axis in human bronchial cells. Mol Cancer Res. 2014;12:775-83 pubmed publisher |
Smith A, Bowers S, Stratman A, Davis G. Hematopoietic stem cell cytokines and fibroblast growth factor-2 stimulate human endothelial cell-pericyte tube co-assembly in 3D fibrin matrices under serum-free defined conditions. PLoS ONE. 2013;8:e85147 pubmed publisher |
Kitazono S, Takiguchi Y, Ashinuma H, Saito Kitazono M, Kitamura A, Chiba T, et al. Effect of metformin on residual cells after chemotherapy in a human lung adenocarcinoma cell line. Int J Oncol. 2013;43:1846-54 pubmed publisher |
Hsu Y, Gu F, Huang Y, Liu J, Ruan J, Huang R, et al. Promoter hypomethylation of EpCAM-regulated bone morphogenetic protein gene family in recurrent endometrial cancer. Clin Cancer Res. 2013;19:6272-85 pubmed publisher |
Bichsel K, Gogia N, Malouff T, Pena Z, Forney E, Hammiller B, et al. Role for the epidermal growth factor receptor in chemotherapy-induced alopecia. PLoS ONE. 2013;8:e69368 pubmed publisher |
Edris B, Fletcher J, West R, van de Rijn M, Beck A. Comparative gene expression profiling of benign and malignant lesions reveals candidate therapeutic compounds for leiomyosarcoma. Sarcoma. 2012;2012:805614 pubmed publisher |
McMellen M, Wakeman D, Erwin C, Guo J, Warner B. Epidermal growth factor receptor signaling modulates chemokine (CXC) ligand 5 expression and is associated with villus angiogenesis after small bowel resection. Surgery. 2010;148:364-70 pubmed publisher |
